Pharma’s Topline Cliff and the Coming Biotech Buyout Wave | Ep. 659
LOEs, Valuations, Growth Projections, Catalysts
Hello Avatar! Welcome to another week of biotech analysis. Today’s commentary is as always on Thursday focused on the general market update. For the week XBI was UP +3% and remains red at -8% for the year. Today we’re digging into the $150B revenue cliff facing large-cap pharma and what it means for biotech. With a wave of patent expirations coming by 2…
Keep reading with a 7-day free trial
Subscribe to BowTiedBiotech to keep reading this post and get 7 days of free access to the full post archives.